SynAct PharmaClinical Stage Biotech Company with focus on Resolution Therapy – A novel approach to fight inflammatory and auto-immune diseases

Lead compound AP1189 in Clinical Phase 2

Press releases

March 31, 2020SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome
March 31, 2020Translation – UK version of Swedish press release – published 08.00 AM. today – SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19
March 31, 2020SynAct Pharma undersöker möjligheten att pröva AP1189 som tilläggsterapi hos inlagda patienter med COVID-19
February 26, 2020SynAct Pharma lanserar ny hemsida på engelska

All press releases

News

October 28, 2019Redeye: Adding an indication
July 5, 2019Kliniska bevis för behandlingseffekter av melanokortiner vid reumatoid artrit
November 7, 2018Sedermeradagen Stockholm
May 15, 2018Presentation på Sedermeradagen Malmö

Calendar

May 11, 2020Sedermeradagen Malmö
June 8, 2020 - June 11, 2020Bio International Convention
October 8, 2020Sedermeradagen Gothenburg

Subscribe to our press releases